View in EDS

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).

Saved in:
Bibliographic Details
Title: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Authors: Blauvelt A; Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com., Ladizinski B; AbbVie Inc, North Chicago, Illinois., Prajapati VH; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Probity Medical Research, Calgary, Alberta, Canada., Laquer V; First OC Dermatology Research, Fountain Valley, California., Fischer A; Southside Dermatology, Tulsa, Oklahoma; Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma., Eisman S; Sinclair Dermatology, East Melbourne, Victoria, Australia., Hu X; AbbVie Inc, North Chicago, Illinois., Wu T; AbbVie Inc, North Chicago, Illinois., Calimlim BM; AbbVie Inc, North Chicago, Illinois., Kaplan B; AbbVie Inc, North Chicago, Illinois., Liu Y; AbbVie Inc, North Chicago, Illinois., Teixeira HD; AbbVie Inc, North Chicago, Illinois., Liu J; AbbVie Inc, North Chicago, Illinois., Eyerich K; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Dermatology and Venerology, School of Medicine, University of Freiburg, Freiburg, Germany.
Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Sep; Vol. 89 (3), pp. 478-485. Date of Electronic Publication: 2023 May 23.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-6787
DOI:10.1016/j.jaad.2023.05.033